Explore the Value of Adding Induction Chemotherapy to Concurrent Chemoradiotherapy in T3-4N0M0 Nasopharyngeal Carcinoma Patients: A Retrospective Study [Corrigendum]

Abstract

Li P, Zhang Q, Luo D, et al. Cancer Manag Res. 2021;13:7067–7076. The authors have advised the affiliation list on page 7067 is incorrect. The correct author list and affiliations are as follows. Peijing Li1,2,*Qun Zhang3,*Donghua Luo4–6Feng Jiang2Qifeng Jin2Yonghong Hua2Ting Jin2Xiaozhong Chen2 1Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, People’s Republic of China; 2Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, 310000, People’s Republic of China; 3Department of Radiation Oncology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510060, People’s Republic of China; 4Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 5State Key Laboratory of Oncology in South China, Guangzhou, 510060, People’s Republic of China; 6Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China Read the original article

Keywords

• nasopharyngeal carcinoma
• chemotherapy
• intensity-modulated radiation therapy.